TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Rituximab and/or Lenalidomide in Treating Patients With Follicular Non-Hodgkin's Lymphoma That is Not Refractory to Rituximab

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
* Documentation of Disease~  * Previously treated, histologically confirmed follicle center cell lymphoma, World Health Organization (WHO) classification, grade 1, 2, or 3a~ * Institutional flow cytometry or immunohistochemistry must confirm Cluster of Differentiation 20 (CD20) antigen expression.~* Prior Treatment~  * Patient must have been treated with rituximab either alone or in combination with chemotherapy.~ * Patient must have a time to progression of ≥ 6 months from last rituximab dose.~ * No corticosteroids within two weeks prior to study, except for maintenance therapy for a non-malignant disease. Maintenance therapy dose may not exceed 20 mg/day prednisone or equivalent.~ * No prior radioimmunotherapy within 12 months of study entry.~* Age ≥ 18 years.~* Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2.~* Measurable disease must be present either on physical examination or imaging studies. Non-measurable disease alone is not acceptable. Any tumor mass \>1 cm is acceptable.Lesions that are considered non-measurable include the following:~  * Bone lesions~ * Ascites~ * Pleural/pericardial effusion~ * Lymphangitis cutis/pulmonis~ * Bone marrow~* No known Central Nervous System (CNS) involvement by lymphoma.~* No known Human Immunodeficiency Virus (HIV) infection.~* Non-pregnant and non-nursing.~* Patients with a currently active second malignancy, other than non-melanoma skin cancers, are not eligible.~* Patients with a recent history (within 3 months of study entry) of Deep Vein Thrombosis/Pulmonary Embolism (DVT/PE) are not eligible.~* Required Initial Laboratory Values:~  * Absolute Neutrophil Count (ANC) ≥ 1000/µL~ * Platelet count ≥ 75,000/µL~ * Creatinine \< 1.5 x Upper Limit of Normal (ULN) unless attributed to lymphoma or calculated clearance \> 50 mL/min (patients on dialysis are not eligible)~ * Total Bilirubin ≤ 2 x ULN unless attributed to lymphoma or Gilbert's disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm I - rituximab (Type: ACTIVE_COMPARATOR): Patients receive rituximab IV on days 1, 8, 15, and 22.
- Arm II - lenalidomide (Type: EXPERIMENTAL): Patients receive oral lenalidomide once daily on days 1-21. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
- Arm III - lenalidomide and rituximab (Type: EXPERIMENTAL): Patients receive lenalidomide as in arm II. Patients also receive rituximab IV on days 8, 15, 22 and 29.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: MI With Text Messaging to Reduce Sexual Risk and Hazardous Drinking Among MSM

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* At least 1 heavy drinking episode or consumption of more than 14 drinks per week over the past month~* At least 1 condomless anal sex episode in past 3 months~* Score of 3 or greater on the Kinsey Scale (Kinsey et al., 1948) indicating at least equally heterosexual and homosexual. Scale ranges from 0 (exclusively heterosexual) to 6 (exclusively homosexual)~Exclusion Criteria:~* Alcohol treatment currently or in past 3 years~* Bipolar disorder or schizophrenia treatment~* Exclusive monogamous relationship

- Gender: MALE
- Minimum Age: 21 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Intervention (Type: EXPERIMENTAL): This intervention arm is a combined in-person text messaging intervention
- Assessment Only Control (Type: NO_INTERVENTION): The is the assessment only comparison condition

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of LJPC-401 for the Treatment of Iron Overload in Adult Patients With Hereditary Hemochromatosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with clinical diagnosis of hereditary hemochromatosis~2. Patients who are prescribed therapeutic phlebotomy for treatment of hereditary hemochromatosis~3. Patients with serum ferritin and TSAT levels above treatment guidelines~4. Female patients of child bearing potential must have a negative pregnancy test and must be using a highly effective method of contraception during participation in the study, and for 30 days after the last dose of study drug~5. Males must be surgically sterile (vasectomy), or using a highly effective method of contraception during participation in the study, and for 30 days after the last dose of study drug~6. Patient must be willing and able to provide written informed consent~Exclusion Criteria:~1. Patients receiving iron chelation therapy within 7 days prior to the first dose of study drug~2. Patients initiating phlebotomy treatments less than 3 months prior to the first dose of study drug~3. Pregnant or lactating women~4. Patients taking an immunosuppressive agent without prior Sponsor approval~5. Patients participating in an unapproved investigational drug or investigational therapeutic device within 30 days of study drug~6. Patients who are unwilling or unable to comply with the study protocol requirements~7. Patients with type 1 or poorly controlled type 2 diabetes~8. Patients with a concomitant disease, disability or condition, including laboratory abnormality and ECG findings, which may interfere with the conduct of the study, or which would, in the opinion of the Investigator, pose an unacceptable risk to the patient in this study, including, but not limited to, clinically significant arrhythmias, alcohol dependency or abuse, drug dependency or abuse, or psychiatric disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LJPC-401 (Type: ACTIVE_COMPARATOR): LJPC-401 solution for subcutaneous injection only, 5mg/1 mL (5mg/mL) or 10mg/1mL (10mg/mL) single use vial
- Placebo (Type: PLACEBO_COMPARATOR): 0.9% Sodium Chloride Injection, USP, or equivalent

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Trial Investigating the Safety, Tolerability, Availability and Distribution in the Body of Once-weekly Long-acting Growth Hormone (Somapacitan) Compared to Once Daily Norditropin NordiFlex® in Adults With Growth Hormone Deficiency

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults with GHD as defined in the consensus guidelines for the diagnosis and treatment of adults with GHD~* Stable human growth hormone (hGH) replacement therapy for at least 3 months~Exclusion Criteria:~* Participation in another clinical trial within 3 months or receipt of any investigational medicinal product within 3 months prior to randomisation~* Active malignant disease or malignant disease within the last 5 years with exception of fully treated local basal cell carcinoma or carcinoma in situ of cervix~* Proliferative retinopathy judged by retina-photo within the last year - only with concomitant diabetes~* Heart insufficiency, New York Heart Association (NYHA) class above 2~* Adults with GHD with poorly controlled diabetes mellitus with a glycosylated haemoglobin (HbA1c) 64 mmol/mol (8.0%) and/or insulin treatment~* Stable pituitary replacement therapy for less than 3 months

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- NNC0195-0092 (somapacitan) (Type: EXPERIMENTAL): None
- Norditropin NordiFlex® (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Efficacy of the Tailored Therapy Based on Antimicrobial Susceptibility for 2nd Eradication of H. Pylori

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* The patients who proved a failure of 1st eradication of H. pylori with Proton pump inhibitor based triple therapy (PPI bid + amoxacillin 1g b.i.d + Clarithromycin 500 mg b.i.d) or sequential therapy (initial 5-day therapy with a combination of PPI b.i.d and amoxicillin 1g b.i.d, followed by 5 days of PPI b.i.d., clarithromycin 500mg b.i.d., and metronidazole 500mg t.i.d) following three methods~  1. positive rapid urease test (CLOtest)~ 2. histologic evidence of H. pylori by modified Giemsa staining~ 3. positive 13C-Urea breath test~* Male and female Korean Adult (Aged ≥ 18 years)~Exclusion Criteria:~* Patients who received two or more eradication therapy for H. pylori infection~* H. pylori eradication failure because of poor compliance~* the administration of antibiotics or the consumption of bismuth salts within 4 weeks or the administration of a proton pump inhibitor (PPI) within 2 weeks~* Advanced gastric cancer or other malignancy~* Abnormal liver function or liver cirrhosis~* Abnormal renal function or chronic kidney disease~* Other severe concurrent diseases~* Previous allergic reactions to the study drugs~* Pregnant or lactating women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- 14 day bismuth based quadruple therapy (PBMT) group (Type: EXPERIMENTAL): Proton pump inhibitor (PPI) regular dose b.i.d., tripotassium dicitrate bismuthate 300 mg q.i.d. (three tablets at 30 min before meals and one tablet at 2 hours after dinner), metronidazole 500 mg t.i.d., and tetracycline 500 mg q.i.d
- 14 day Moxifloxacin containing triple therapy (MEA) group (Type: EXPERIMENTAL): PPI regular dose b.i.d., moxifloxacin 400 mg q.d., and amoxicillin 1g b.i.d.
- 14 day tailored therapy group (Type: ACTIVE_COMPARATOR): based on H. pylori culture and antimicrobial sensitivity, select the 2nd rescue regimen between 14 days of bismuth-based quadruple therapy or 14 days moxifloxacin-containing triple therapy according to antibiotics susceptibility.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Wayfinding Intervention in High-Fidelity Long-Term Memory

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* fluent speakers of English~* completed 12 or more years of education~* normal or corrected-to-normal vision~* dexterity to comfortably operate the scanner-compatible response box~* freedom from physical and neurological conditions contra-indicated for fMRI~* must confirm physical stamina and comfort for 45-minute, brisk walks on level ground~Exclusion Criteria:~* use of psychotropic medications~* history of concussions or dizziness, vestibular or balance problems~* significant discomfort with virtual reality experiences

- Gender: ALL
- Minimum Age: 62 Years
- Maximum Age: 85 Years
- Healthy Volunteers: t

Study Arms:
- LabyrinthVR Trackers (Type: EXPERIMENTAL): Multi-session cognitive intervention with head-mounted display virtual reality computer game that presents an adaptive spatial wayfinding challenge. Game movement via participant ambulation wearing leg-position trackers.
- LabyrinthVR Scoot (Type: EXPERIMENTAL): Multi-session cognitive intervention with head-mounted display virtual reality computer game that presents an adaptive spatial wayfinding challenge. Game movement via teleporting technique.
- Placebo Controls (Type: PLACEBO_COMPARATOR): Multi-session cognitive intervention with handheld tablet or wireless virtual reality headset presentation of commercially available, narrative computer games.
- Coherence (Type: ACTIVE_COMPARATOR): Multi-session cognitive intervention with head-mounted display virtual reality computer game that presents an adaptive rhythm training game.
- Labyrinth Tablet (Type: EXPERIMENTAL): Multi-session cognitive intervention with tablet computer, displaying 2.5D version of Labyrinth game in an adaptive spatial wayfinding challenge. Game movement via on-screen control buttons.
- Labyrinth VR wireless (Type: EXPERIMENTAL): Multi-session cognitive intervention with head-mounted display virtual reality computer game using wireless, narrower filed technology to presents an adaptive spatial wayfinding challenge. Game movement via teleporting technique.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study for Newly Diagnosed Follicular Lymphoma Patients With a Large Tumor Burden

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed follicular lymphoma with a biopsy performed in the last 3 months~* Patients previously untreated.~* Patients with at least one of the following symptoms requiring initiation of treatment:~  * Bulky disease at study entry according to the Groupe d'Etudes Lymphomes Folliculare (GELF) criteria: nodal or extranodal mass \> 7cm in its greater diameter~ * B symptoms~ * Eastern Cooperative Oncology Group (ECOG) performance status (PS) \> 1~ * Elevated serum lactate dehydrogenase (LDH) or beta2-microglobulin~ * Involvement of at least 3 nodal sites (each with a diameter greater than 3 cm)~ * Symptomatic splenic enlargement~ * Compressive syndrome~ * Pleural/peritoneal effusion~* Age must be \> 18 years and less than 76 years~* Having previously signed a written informed consent form.~Exclusion Criteria:~* Transformation to high-grade lymphoma (secondary to low-grade follicular lymphoma).~* Patients without a large tumor burden.~* Patients with prior or concomitant malignancies except non-melanoma skin cancer or adequately treated in situ cervical cancer.~* Poor renal function: Serum creatinine \> 150 μmol/L,~* Known HIV infection or active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection.~* Patients with contra-indication to interferon, adriamycin, or rituximab.~* Serious underlying medical conditions, which could impair the ability of the patient to participate in the trial (e.g. ongoing infection, uncontrolled diabetes mellitus, gastric ulcers, active autoimmune disease). Judgment is up to the investigator.~* Known sensitivity or allergy to murine products~* Adult patient under tutelage.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of COR-001

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
INCLUSION CRITERIA~1. Age greater than or equal to 18 years at the time of signing of the ICF.~2. The patient agrees to comply with the contraception and reproduction restrictions of the study~3. Receiving intravenous (IV) or subcutaneous (SC) erythropoietin stimulating agents (ESA) drugs continuously prescribed for a minimum of 8 weeks prior to Screening~4. At least 2 ferritin values during Screening \> 300 ng/mL~5. At least 2 transferrin saturation (TSAT) values during Screening between 15% and 50% (inclusive)~EXCLUSION CRITERIA:~1. Use of systemic immunosuppressive drugs during the Screening Period or anticipated use of such drugs any time during the study~2. Clinical evidence or suspicion of active or smoldering infection by clinical or serologic criteria~3. Actively treated or active malignancy~4. Known or suspected occult or active bleeding~5. Received a red blood cell or whole blood transfusion within 2 months prior to Screening or anticipated to receive a blood transfusion at any time during the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- COR-001 (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Improving Comprehensive Cancer Screening Among Vulnerable Patients Using Patient Navigation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SCREENING
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 21-75~* Seen in MGPC Practices within the Past 3 Years~* Linked to a Specific PCP or to a Specific Practice~Exclusion Criteria:~* A PCP Outside of the MGPC-PBRN network~* Greater Than 75 Years Old~* MGH Chelsea Health Center Patients

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Patient Navigation Intervention (Type: EXPERIMENTAL): Participants randomized to the intervention arm were transferred to a navigator roster within the TopCare application for the 8-month study period. Navigators utilized TopCare to track these participants, reach out to them in their own language, and provide intense outreach to help them complete cancer screening.
- Standard of Care - No Intervention (Type: NO_INTERVENTION): Participants randomized to the control arm received usual care within TopCare, which meant that clinicians and staff could elect to send the participant a reminder letter about their overdue cancer screening exams, reach out to schedule overdue exams, or document appropriate reasons for deferral or exclusion.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Single Group Study of the Safety of and Immune Response to a Bird Flu Vaccine (H7N3) in Healthy Adults

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Good general health~* Available for the duration of the trial~* Willing to use acceptable forms of contraception for the duration of the study~Exclusion Criteria:~* Clinically significant neurologic, heart, lung, liver, rheumatologic, autoimmune, or kidney disease~* Behavioral or cognitive impairment or psychiatric disease that, in the opinion of the investigator, may affect study participation~* Previously enrolled in an H7N3 influenza vaccine trial or in any study of an avian influenza vaccine~* Seropositive to the H7N3 influenza A virus (serum hemagglutination inhibition \[HI\] titer greater than 1:8)~* Illegal drug use or dependency determined by urine test~* Medical, work, or family problems as a result of alcohol or illicit drug use within 12 months prior to study entry~* History of severe allergic reaction~* Allergy to oseltamivir~* Asthma or reactive airways disease within 2 years prior to study entry~* History of Guillain-Barre syndrome~* HIV infected~* Hepatitis C virus infected~* Positive for hepatitis B surface antigen (HBsAg)~* Known immunodeficiency syndrome~* Use of corticosteroids or immunosuppressive drugs within 30 days prior to vaccination. Participants who have used topical corticosteroids are not excluded.~* Live vaccines within 4 weeks prior to study vaccination~* Killed vaccines within 2 weeks prior to study vaccination~* Absence of spleen~* Blood products within 6 months prior to study vaccination~* Current smoker unwilling to stop smoking for the duration of the study~* Have traveled to the Southern Hemisphere, Asia, or the United Kingdom within 14 days prior to study vaccination~* Have traveled on a cruise ship within 14 days prior to study vaccination~* Work in the poultry industry~* Other investigational vaccine or drug within 30 days prior to study vaccination~* Allergy to eggs or egg products~* Purified protein derivative (PPD) positive (positive tuberculosis \[TB\] test)~* Have family member with immunodeficiency~* Other condition that, in the opinion of the investigator, may interfere with the study~* Pregnancy or breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 49 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): 0.50 ml (0.25 ml in each nostril) of Influenza A Vaccine H7N3 (6-2) AA ca Recombinant (A/chicken/British Columbia/CN-6/2004 x A/Ann Arbor/6/60 ca) administered by nasal spray at two timepoints (at study entry and between Weeks 4 and 8)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete